Why Did Neogenomics Plunge 15.94% Despite Beating EPS Estimates?

On July 29, 2025, Neogenomics experienced a significant drop of 15.94% in pre-market trading, reflecting a notable shift in investor sentiment.

Neogenomics reported its second-quarter 2025 results, revealing a 10% increase in revenue to $181 million compared to the same period last year. However, the company posted a net loss of $45 million and saw its cash reserves decrease to $155 million following the repayment of 2025 convertible notes.

The company's earnings per share (EPS) for the quarter was $0.03, surpassing analyst estimates of $0.02. Despite this positive earnings surprise, revenue fell short of expectations, which may have contributed to the stock's decline. The company's pharmaceutical revenue, in particular, was cited as a drag on overall performance.

Looking ahead, Neogenomics expects full-year earnings to be in the range of 8 cents to 12 cents per share. The company's guidance and recent financial performance will be closely watched by investors as they assess the long-term prospects of the oncology diagnostics firm.